Lamivudine
Product Images NDC 53808-0844

5 FDA label images from State Of Florida Doh Central Pharmacy · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lamivudine (NDC 53808-0844). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

150mg-60s-btl (Lamivudine 150mg Apotex)

150mg-60s-btl (Lamivudine 150mg Apotex)
LAMIVUDINE 150 mg tablets packaging label from DOH Central Pharmacy, Tallahassee, FL. The label includes the proprietary name, dosage strength, and distributor information, along with a barcode and lot number.*
FDA Label Image

300mg-30s-btl (Lamivudine 300mg Apotex)

300mg-30s-btl (Lamivudine 300mg  Apotex)
Packaging label for Lamivudine 300 mg tablets, labeled as prescription only. The label indicates the product is packaged by DOH Central Pharmacy in Tallahassee, FL, and includes a barcode and UPC number.*
FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
Chemical structure of Lamivudine with a methanol solvate (0.2 CH3OH) depicted, showing its molecular composition and arrangement as provided by State of Florida DOH Central Pharmacy.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A pharmacokinetic graph depicting systemic clearance of a drug versus age in years. The curve shows a decreasing trend in systemic clearance as age increases from 0 to 60 years, leveling off somewhat at older ages. The vertical axis represents systemic clearance, and the horizontal axis represents age in years.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A line graph depicting proportions of patients with HIV-1 RNA less than 400 copies/mL over 48 weeks of treatment. It compares Lamivudine 150 mg twice daily and Lamivudine 300 mg once daily, showing similar trends in viral suppression over time on the x-axis (weeks), with the y-axis representing proportion percentages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.